Fred Hutchinson
B-cell maturation antigen-targeted CAR T-cell therapy potent in advanced myeloma

SAN DIEGO — B-cell maturation antigen chimeric antigen receptor T cells that harbor a fully human single-chain variable fragment with a defined composition of CD4-positive and CD8-positive T cells appeared potent among patients with heavily pretreated, high-risk multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.
Risk adjustment ‘negates benefit’ of stem cell transplant for acute myeloid leukemia

SAN DIEGO — The addition of a transplant-specific comorbidity score to risk stratification appeared to negate the survival benefit of hematopoietic stem cell transplantation among older patients with acute myeloid leukemia, according to results of a prospective, multicenter, longitudinal study presented at ASH Annual Meeting and Exposition.
Novel risk stratification model outperforms standard prediction tools for myelodysplastic syndrome
Progressive disease after anti-CD19 CAR T-cell therapy predicts poor lymphoma survival
Consolidative transplant after CAR T-cell therapy may benefit certain patients with acute lymphoblastic leukemia
SAN DIEGO — Consolidative hematopoietic stem cell transplant after CD19-directed chimeric antigen receptor T-cell therapy prolonged leukemia-free survival for certain pediatric and young adult patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia, according to results of the PLAT-02 trial presented at ASH Annual Meeting and Exposition.